Abstract: The present invention discloses a compound of the formula (I), which acts as an agonist of adenosine monophosphate-activated protein kinase, which induce phosphorylation and activation of AMPK?, thereby further regulating downstream signaling pathways, inhibiting growth and proliferation of liver cancer cells and breast cancer cells, and also inducing apoptosis of adipocytes. Therefore, the compound provided by the present invention can be utilised for treatment and preparation of pharmaceutical composition for cancer, and lipid metabolism-related diseases or syndromes mediated by AMPK.

Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof is provided. In formula (I), Ar is indazole, 5-isoquinoline, 6-isoquinoline, or their N-oxide. X is —C(?Z)—, wherein Z is N—CN, NH, NR4, NCOR4, NCONR4R5, NCO-aryl, S, or O. Y and J are independently H, alkyl, aryl, aminoalkyl, —NH2, —CN, —OH, —O-alkyl, —O-aryl, —COOH, —COOR4, —CONHR4, —CONHCH2-aryl, —CONR4CH2-aryl, —NHCOR4, halogen, halogened alkyl, -alkyl-OR4, -alkyl-ONO2, alkyl-ONO2, —OCOOR4, —O(C?O)-aryl, —CHR4OH, —CH2OH, —CH2O(C?O)-aryl, —CH2O(C?O)—R4, —CHR4O(C?O)-aryl, —CHR4O(C?O)—R4, unsaturated carboxylic ester, substituted alkynyl, —NHSO2R4, —SO2R4, —SO2NHR4, or —SO2NR4R5, or Y and J bond together to form a carbocylic or aromatic ring, wherein R4 and R5 are independently H, substituted C1-C6 alkyl, substituted aryl, cycloalkyl, alkylaryl, -alkyl-NR6R7, —S(O)0-2-(alkyl-NR6R7).

Abstract: The present invention discloses a compound of the formula (I), which acts as an agonist of adenosine monophosphate-activated protein kinase, which induce phosphorylation and activation of AMPK?, thereby further regulating downstream signaling pathways, inhibiting growth and proliferation of liver cancer cells and breast cancer cells, and also inducing apoptosis of adipocytes. Therefore, the compound provided by the present invention can be utilised for treatment and preparation of pharmaceutical composition for cancer, and lipid metabolism-related diseases or syndromes mediated by AMPK.

Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof is provided. In formula (I), Ar is indazole, 5-isoquinoline, 6-isoquinoline, or their N-oxide. X is —C(?Z)—, wherein Z is N—CN, NH, NR4, NCOR4, NCONR4R5, NCO-aryl, S, or O. Y and J are independently H, alkyl, aryl, aminoalkyl, —NH2, —CN, —OH, —O-alkyl, —O-aryl, —COOH, —COOR4, —CONHR4, —CONHCH2-aryl, —CONR4CH2-aryl, —NHCOR4, halogen, halogened alkyl, -alkyl-OR4, -alkyl-ONO2, alkyl-ONO2, —OCOOR4, —O(C?O)-aryl, —CHR4OH, —CH2OH, —CH2O(C?O)-aryl, —CH2O(C?O)—R4, —CHR4O(C?O)-aryl, —CHR4O(C?O)—R4, unsaturated carboxylic ester, substituted alkynyl, —NHSO2R4, —SO2R4, —SO2NHR4, or —SO2NR4R5, or Y and J bond together to form a carbocylic or aromatic ring, wherein R4 and R5 are independently H, substituted C1-C6 alkyl, substituted aryl, cycloalkyl, alkylaryl, -alkyl-NR6R7, —S(O)0-2-(alkyl-NR6R7).

Abstract: A small interfering RNA is provided. The small interfering RNA consists of a passenger strand and a guide strand, wherein the sequence of the passenger strand comprises the sequence of SEQ ID NO. 7, and the sequence of the guide strand comprises the sequence of SEQ ID NO. 8, wherein the small interfering RNA is capable of inhibiting galectin-12 expression.

Abstract: A small interfering RNA is provided. The small interfering RNA consists of a passenger strand and a guide strand, wherein the sequence of the passenger strand comprises the sequence of SEQ ID NO. 7, and the sequence of the guide strand comprises the sequence of SEQ ID NO. 8, wherein the small interfering RNA is capable of inhibiting galectin-12 expression.

Abstract: A method for estimating image conversion parameters is revealed. Firstly, using an image capturing unit to capture at least one captured image of an object to an image processing unit for calculation. The image processing unit can take linear brightness change of single captured image to estimate the image conversion parameters, also can take comparison of linear and non-linear images to estimate the image conversion parameters, further can take the difference of exposure quantities to estimate the image conversion parameters. Therefore, the estimation of the image conversion parameters can be finished well and easily.

Abstract: A motion detection system is disclosed. The invention comprises a touch panel, a plurality of switching units, a detection unit and a control unit. The touch panel comprises a plurality of metal sensors, each of which in turn is set as a detecting sensor. Each switching unit is electrically connected to a corresponding metal sensor respectively for switching voltage. During a charge stage, the detection unit calculates the discharge time of the detecting sensor and generates a detection result signal. The control unit generates a motion signal according to the detection result signal generated by the detection unit. Based on the capacitive effect and simple hardware architecture, the invention can be employed in option or orientation control by detecting a human hand's movement on the touch panel.

Abstract: A motion detection system is disclosed. The invention comprises a touch panel, a plurality of switching units, a detection unit and a control unit. The touch panel comprises a plurality of metal sensors, each of which in turn is set as a detecting sensor. Each switching unit is electrically connected to a corresponding metal sensor respectively for switching voltage. During a charge stage, the detection unit calculates the discharge time of the detecting sensor and generates a detection result signal. The control unit generates a motion signal according to the detection result signal generated by the detection unit. Based on the capacitive effect and simple hardware architecture, the invention can be employed in option or orientation control by detecting a human hand's movement on the touch panel.